09839689 cites 95 patents.

The present invention concerns methods and compositions for treatment of HIV infection in a subject, utilizing a DNL® complex comprising at least one anti-HIV therapeutic agent, attached to an antibody, antibody fragment or PEG. In a preferred embodiment, the antibody or fragment binds to an antigen selected from gp120, gp41, CD4 and CCR5. In a more preferred embodiment the antibody is P4/D10 or 2G12, although other anti-HIV antibodies are known and may be utilized. In a most preferred embodiment, the anti-HIV therapeutic agent is a fusion inhibitor, such as T20, T61, T651, T1249, T2635, CP32M or T-1444, although other anti-HIV therapeutic agents are known and may be utilized. The DNL® complex may be administered alone or may be co-administered with one or more additional anti-HIV therapeutic agents.

Title
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
Application Number
14/969901
Publication Number
9839689 (B2)
Application Date
December 15, 2015
Publication Date
December 12, 2017
Inventor
David M Goldenberg
Mendham
NJ, US
Chien Hsing Chang
Downingtown
PA, US
Agent
Richard A Nakashima
Assignee
IBC Pharmaceuticals
NJ, US
IPC
A61K 39/00
A61K 47/48
A61K 31/704
C07K 19/00
C07K 16/10
A61K 31/00
A61K 39/395
View Original Source